Brief: Bioxyne Posts HY Loss Attributable A$12.3 Million
Feb 29 (Reuters) - Bioxyne Ltd BXN.AX :
* HY LOSS ATTRIBUTABLE A$12.3 MILLION VERSUS LOSS A$818,424
* HY REVENUES FROM CONTINUING OPERATIONS A$4.9 MILLION
VERSUS
A$2.4 MILLION
Source text for Eikon: ID:nASX66P4xz
Further company coverage: BXN.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN